

Printed by Larry Page on 7/10/2015 4:47:24 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Promyelocytic Leukemia (APL)
Specific Indication:	
Molecular Abnormality:	(15;17) translocation
Test:	(15;17) translocation
Chromosome:	t(15;17)
Gene Symbol:	PML-RARA
Test Detects:	Translocation
Methodology:	Cytogenetics, Molecular testing
NCCN Category of Evidence:	2A
Specimen Types:	Bone marrow
NCCN Recommendation - Clinical Decision:	APL Classification (AML-2) OR t(15;17) confers better risk status (AML-A)
Test Purpose:	Classification, Prognostic
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-A Page:20, AML-2 Page:7
Notes:	
Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 82	

Printed by Larry Page on 7/10/2015 4:47:24 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Promyelocytic Leukemia (APL)
Specific Indication:	
Molecular Abnormality:	(15;17) translocation
Test:	(15;17) translocation
Chromosome:	t(15;17)
Gene Symbol:	PML-RARA
Test Detects:	Translocation
Methodology:	PCR
NCCN Category of Evidence:	2A
Specimen Types:	Bone marrow, Peripheral blood
NCCN Recommendation - Clinical Decision:	Document molecular remission after consolidation; Monitor by PCR. PCR should be performed on a marrow sample at completion of consolidation to document molecular remission. Subsequent monitoring by PCR can be done with peripheral blood, although marrow is a more sensitive monitoring technique and may give earlier signs of relapse (further details, AML-5 footnote bb, cc).
Test Purpose:	Monitoring
When to Test:	Post-consolidation therapy
Guideline Page with Test Recommendation:	AML-5 Page:10, AML-6 Page:11
Notes:	
Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 83	